Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Peptomyc logo — Developing Peptides to treat Cancer

Peptomyc

Developing Peptides to treat Cancer

Founded 2014 Spain Spain 22 employees Unknown Total: $43.77M Biotechnology, Health Care +1

General Information

Company Name Peptomyc
Founded Year 2014
Location Spain Spain +1
Employees 22
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Unknown
Social

Get notified when Peptomyc moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Peptomyc

Peptomyc, with its slogan "Developing Peptides to treat Cancer", is prominently positioned at the intersection of Biotechnology and Health Care. Founded in 2014, this Spain-based company is pioneering a new class of cell-penetrating peptides (CPPs) aimed at targeting the notorious Myc oncoprotein, a formidable contributor to cancer progression.

The company’s foundation stems from over two decades of scientific research spearheaded by Dr. Soucek, focusing on Omomyc, the most effective direct Myc inhibitor thus far. This strong research background equips Peptomyc with a unique competitive edge in the oncological therapeutics space.

In a recent funding round dated 01 June 2023, Peptomyc secured a $2.49M early VC investment from the European Innovation Council. This capital injection not only underscores investor confidence but also brings the company a step closer to revolutionizing cancer treatment.

Taxonomy: Cell Penetrating Peptides, Myc Oncoprotein, Cancer Treatment, Omomyc, Drug Development, Oncology, Myc Inhibition, Precision Medicine, Glioblastoma, Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Cancer Resistance, Novel Therapeutics, VHIO Collaboration

Services & Products

Development of MYC inhibitory drugs
Clinical trial management
Biotechnological research and innovation

Target Customers

Cancer patients with abnormal MYC activity Healthcare providers Oncology research institutions Pharmaceutical partners

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC •••••• 1
Investor
01 Jun 2023
Late Vc •••••• 4
Investor Investor Investor
•••• •••• 		01 Jan 2022
Late Vc •••••• 4
Investor Investor Investor
•••• •••• 		01 Dec 2020
Grant •••••• 1 •••• •••• 01 Jul 2019
Support Program •••••• 1
Investor
01 Sep 2017

View All 12 Funding Rounds

Peptomyc Alternatives & Competitors

Peptomyc vs
Kronos Bio
Kronos Bio United States

We’re focused on creating a world where no life is cut short by cancer or other serious diseases.

Private Equity
70 employees
Biotechnology, Health and Wellness
Peptomyc vs
Gibson Oncology, LLC
Gibson Oncology, LLC

- Tough on cancer. Not on Patients.

4 employees
Biotechnology, Health Care
Peptomyc vs
Mark Young Construction, LLC
Mark Young Construction, LLC United States

Whether it's the local fire station, special project, or neighborhood grocer, we build where communi...

110 employees
Real Estate

FAQ About Peptomyc

Developing Peptides to treat Cancer
Peptomyc was founded in 2014.
Peptomyc is headquartered in Spain.
Peptomyc operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Peptomyc has approximately 22 employees.
Peptomyc has completed 12 funding rounds, raising a total of $43.77M. The latest funding stage is Unknown.
Peptomyc offers: Development of MYC inhibitory drugs, Clinical trial management, Biotechnological research and innovation.
Top alternatives and competitors to Peptomyc include Kronos Bio, Gibson Oncology, LLC , Mark Young Construction, LLC, 2seventy bio, NovaRx Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Peptomyc and Kronos Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Peptomyc and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy